Compared to gemcitabine, the commonly used chemotherapeutic agent for PDA, PBI-05204 exhibited strong monotherapeutic antineoplastic effects through down regulation of PI3k/mTOR pathways and augmentation of the antitumor efficacy of gemcitabine. This evidence concerns the gene MTOR and Patent ductus arteriosus.